Table 1
Haematological data of patients and results of the human androgen receptor gene assay (HUMARA) clonality studies
| Patient | Diagnosis | Age | BCR/ ABL | Hb | WBC | Differential blood count | Plt | N-clon | L-clon |
|---|---|---|---|---|---|---|---|---|---|
| Diagnosis: aCML, atypical chronic myeloid leukaemia; CIMF, chronic idiopathic myelofibrosis; CML, chronic myelogenous leukaemia (chronic phase); CMML, chronic myelomonocytic leukaemia; CNL, chronic neutrophilic leukaemia; LR, leukaemoid reaction; PCV, polycythaemia vera; Sharp sy., Sharp syndrome (a mixed connective tissue disease). Age, age at time of diagnosis; BCR/ABL, status of BCR/ABL translocation; Hb, haemoglobin concentration (g/l); WBC, white blood cell count (×109/l); differential blood count: Seg, segmented neutrophils; Bn, bands; My, myelocytes; Bas(ophils), Eo(sinophils), Ly(mphocytes), Mo(nocytes), Ery(throblasts); Plt, platelet count (×109/l); N-clon/L-clon, clonal status of neutrophils and phytohaemagglutinin expanded lymphocytes using HUMARA with the patterns (M) monoclonal and (P) polyclonal; NI, not informative; ND, not determined. | |||||||||
| 1 | CNL | 52 | Absent | 140 | 30.0 | Seg 70, Bn 3, My 9, Bas 1, Eo 2, Ly 10, Mo 5 | 182 | M | M |
| 2 | CNL | 81 | Absent | 108 | 35.0 | Seg 90, Bn 0, My 0, Bas 0, Eo 0, Ly 9, Mo 1 | 189 | M | P |
| 3 | CNL | 37 | Absent | 143 | 36.2 | Seg 64, Bn 15, My 13, Bas 0, Eo 0, Ly 7, Mo 1 | 273 | M | M |
| 4 | CNL | 72 | Absent | 89 | 38.0 | Seg 41, Bn 13, My 37, Bas 0, Eo 0, Ly 6, Mo 3 | 47 | M | M |
| 5 | CNL | 63 | Absent | 123 | 24.6 | Seg 60, Bn 6, My 17, Bas 5, Ery 2, Ly 9, Mo 1 | 210 | M | M |
| 6 | CML | 60 | b2a2 | 98 | 83.5 | Seg 28, Bn 14, My 39, Bas 1, Eo 1, Ly 10, Mo 7 | 718 | M | P |
| 7 | CML | 53 | b3a2 | 101 | 46.1 | Seg 63, Bn 4, My 12, Bas 0, Eo 1, Ly 13, Mo 7 | 365 | M | P |
| 8 | CML | 41 | b3a2 | 98 | 239.0 | Seg 45, Bn 5, My 39, Bas 3, Eo 0, Ly 2, Mo 6 | 619 | M | P |
| 9 | aCML | 48 | Absent | 142 | 32.7 | Seg 27, Bn 4, My 46, Bas 3, Eo 1, Ly 15, Mo 4 | 460 | M | P |
| 10 | CML | 64 | b2a2 | 116 | 39.2 | Seg 80, Bn 7, My 0, Bas 0, Eo 1, Ly 7, Mo 5 | 486 | M | P |
| 11 | CML | 58 | b3a2 | 136 | 24.1 | Seg 63, Bn 7, My 0, Bas 2, Eo 0, Ly 22, Mo 6 | 439 | M | M |
| 12 | CML | 65 | b3a2 | 130 | 33.9 | Seg 59, Bn 4, My 22, Ery 4, Bas 5, Eo 2, Ly 6, Mo 1 | 246 | M | P |
| 13 | CMML | 83 | Absent | 100 | 37.2 | Seg 63, Bn 0, My 0, Bas 0, Eo 0, Ly 9, Mo 28 | 191 | M | P |
| 14 | CMML | 74 | Absent | 114 | 8.2 | Seg 20, Bn 6, My 0, Bas 0, Eo 0, Ly 51, Mo 23 | 95 | M | P |
| 15 | PCV | 61 | Absent | 91 | 15.4 | Seg 80, Bn 4, Ery 4, Bas 0, Eo 0, Ly 10, Mo 2 | 44 | M | ND |
| 16 | CIMF | 73 | Absent | 105 | 12.2 | Seg 78, Bn 0, My 0, Bas 1, Eo 4, Ly 16, Mo 1 | 124 | M | P |
| 17 | CIMF | 83 | Absent | 116 | 30.4 | Seg 38, Bn 4, My 19, Bas 5, Eo 7, Ly 20, Mo 7 | 403 | M | P |
| 18 | LR (smoker) | 39 | Absent | Normal | 14.0 | Seg 63, Bn 2, My 2, Bas 1, Eo 4, Ly 25, Mo 3 | Normal | M | P |
| 19 | LR (diabetes) | 50 | Absent | 88 | 10.4 | Seg 61, Bn 0, My 0, Bas 0, Eo 3, Ly 32, Mo 4 | 348 | P | P |
| 20 | LR (fever) | 63 | ND | 99 | 18.1 | Seg 87, Bn 1, Eo 2, Ly 8, Mo2 | 518 | P | P |
| 21 | LR | 67 | ND | ND | 21.5 | ND | ND | P | P |
| 22 | LR (diabetes) | 93 | ND | ND | 20.1 | ND | ND | M | ND |
| 23 | LR (smoker) | 37 | ND | 134 | 13.6 | Seg 69, Bn 1, Ly24, others 6 | 204 | P | P |
| 24 | LR (Sharp sy.) | 50 | ND | 90 | 7.0 | Seg 80, Bn 1, Bas 1, Eo 5, Ly 7, Mo 6 | 307 | M | P |
| 25 | LR | 53 | Absent | 142 | 13.8 | Seg 56, Bn 2, Ly35, Mo 7 | 354 | NI | NI |
| 26 | LR (smoker) | 45 | Absent | 129 | 12.5 | Seg 66, Bn 4, Eo 6, Ly 20, Mo 4 | 403 | P | P |
| 27–52 | Blood donors | 20–77 | ND | ND | Normal | * | ND | See text | |
